NASDAQ NMS - GLOBAL MARKET · KNSA
+0.30% · +$0.2200 · Vol 17.5K
Live · updated 09:37:20 ET
Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals International PLC

Biotechnology
$75.44
Card
Relationship Map

Follow $KNSA

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $KNSA by email

Veridion Score

BETAHIGH CONF · 6 of 6 factors measuredMethodology
KNSA
Kiniksa Pharmaceuticals International PLC
Thu Oct 1 · last completed session · daily score · 15h old
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

69/ 100
Veridion Score
Upper range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Thu Oct 1 · last completed session · daily score · 15h old
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is KNSA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading KNSA catalysts
About Kiniksa Pharmaceuticals International PLC
PHARMACEUTICAL PREPARATIONS
Listed since
2018
Employees
366
Country
GB

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$75.58
Day high
$75.69
Day low
$74.56
Previous close
$75.22
52W high
$80.92
-6.77% from high
52W low
$37.01
88% of range
Market cap
$5.9B
P/E
72.94×
EPS
$0.9828
Beta
0.14
Shares out
78M
Volume
17.5K
0.03× rel vol
Avg volume
539.1K
VWAP
$75.35
Price history computed in-house
1W
+0.49%
1M
-5.56%
3M
+16.91%
1Y
+101.35%
YTD
+82.90%
SMA 50 $76.75 · below
SMA 200 $56.04 · above
52W position 88%

KNSA overview

Veridion Score
69
Registered · 2026-10-01
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around KNSA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading KNSA Form 4 filings
Public disclosures

Congress activity in KNSA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for KNSA in the cached public ledger.

Federal contracts

KNSA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KNSA in this window.
Lobbying spend

KNSA lobbying filings, year to date.

Registered lobbying filings matched to Kiniksa Pharmaceuticals International PLC.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KNSA in this window.
Loading news for KNSA
Analyst ratings
Sovereign unlock shows live analyst consensus for KNSA.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.